NRx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3.39	1.23	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Cost of Revenue	1.81	0.51	-	-	-	-
Gross Profit	1.58	0.72	-	-	-	-
Selling, General & Admin	15.93	13.06	13.5	14.22	27.31	74.94
Research & Development	5.41	3.78	6.2	13.37	17.03	20.26
Other Operating Expenses	-	-	-	-	-	-0.77
Operating Expenses	21.55	16.91	19.7	27.59	44.34	94.43
Operating Income	-19.96	-16.19	-19.7	-27.59	-44.34	-94.43
Interest Expense	-1.14	-0.67	-0.23	-0.12	-	-0.02
Interest & Investment Income	0.02	0.01	0.04	0.49	0.25	-
Other Non Operating Income (Expenses)	-5.02	-7.77	-3.78	0.02	0.26	1.69
EBT Excluding Unusual Items	-26.1	-24.61	-23.67	-27.19	-43.83	-92.76
Gain (Loss) on Sale of Investments	-0.04	-0.04	-	-	-	-
Other Unusual Items	2.66	-3.98	-1.45	-2.96	4.08	-0.31
Pretax Income	-23.48	-28.62	-25.13	-30.15	-39.75	-93.06
Net Income	-23.48	-28.62	-25.13	-30.15	-39.75	-93.06
Preferred Dividends & Other Adjustments	-	-	-	0.01	-	-
Net Income to Common	-23.48	-28.62	-25.13	-30.16	-39.75	-93.06
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	30	21	11	8	7	5
Shares Outstanding (Diluted)	30	21	11	8	7	5
Shares Change	110.42%	101.06%	40.50%	15.20%	40.17%	36.90%
EPS (Basic)	-0.78	-1.34	-2.36	-3.98	-6.04	-19.84
EPS (Diluted)	-0.78	-1.34	-2.36	-3.98	-6.04	-74.40
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-20.67	-14.11	-10.64	-21.66	-39.77	-37.71
Free Cash Flow Per Share	-0.68	-0.66	-1.00	-2.86	-6.05	-8.04
Gross Margin	46.64%	58.78%	-	-	-	-
Operating Margin	-588.21%	-1321.47%	-	-	-	-
Profit Margin	-691.81%	-2336.49%	-	-	-	-
Free Cash Flow Margin	-609.04%	-1152.00%	-	-	-	-
EBITDA	-19.76	-16.12	-19.7	-27.58	-44.33	-94.43
D&A For EBITDA	0.2	0.07	0.01	0.01	0	0
EBIT	-19.96	-16.19	-19.7	-27.59	-44.34	-94.43

SEC Filings: 10-K · 10-Q